110 related articles for article (PubMed ID: 12517774)
1. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
Byrd JC; Smith L; Hackbarth ML; Flinn IW; Young D; Proffitt JH; Heerema NA
Cancer Res; 2003 Jan; 63(1):36-8. PubMed ID: 12517774
[TBL] [Abstract][Full Text] [Related]
2. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
3. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
4. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
[TBL] [Abstract][Full Text] [Related]
5. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations.
López C; Delgado J; Costa D; Conde L; Ghita G; Villamor N; Navarro A; Cazorla M; Gómez C; Arias A; Muñoz C; Baumann T; Rozman M; Aymerich M; Colomer D; Cobo F; Campo E; López-Guillermo A; Montserrat E; Carrió A
Genes Chromosomes Cancer; 2012 Sep; 51(9):881-9. PubMed ID: 22619094
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
7. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
8. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
[TBL] [Abstract][Full Text] [Related]
10. [Molecular cytogenetic characteristics of chronic lymphocytic leukemia].
Xu W; Li JY; Pan JL; Qiu HR; Shen YF; Xiao B; Chen LJ; Wu YF; Sheng RL; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):349-52. PubMed ID: 17044998
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
Tam CS; Otero-Palacios J; Abruzzo LV; Jorgensen JL; Ferrajoli A; Wierda WG; Lerner S; O'Brien S; Keating MJ
Br J Haematol; 2008 Apr; 141(1):36-40. PubMed ID: 18324964
[TBL] [Abstract][Full Text] [Related]
12. Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia.
Sindelárová L; Michalová K; Zemanová Z; Ransdorfová S; Brezinová J; Peková S; Schwarz J; Karban J; Cmunt E
Cancer Genet Cytogenet; 2005 Jul; 160(1):27-34. PubMed ID: 15949567
[TBL] [Abstract][Full Text] [Related]
13. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
[TBL] [Abstract][Full Text] [Related]
14. Detection of chromosomal abnormalities in chronic lymphocytic leukemia increased by interphase fluorescence in situ hybridization in tetradecanoylphorbol acetate-stimulated peripheral blood cells.
Sánchez J; Aventín A
Cancer Genet Cytogenet; 2007 May; 175(1):57-60. PubMed ID: 17498559
[TBL] [Abstract][Full Text] [Related]
15. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
[TBL] [Abstract][Full Text] [Related]
16. [Importance of prognostic factors in patients with chronic B-lymphocytic leukemia at the time of diagnosis].
Cmunt E; Michalová K; Sindelárová L; Karban J; Zemanová Z; Kurková S; Brezinová J; Schwarz J; Bosáková Z
Sb Lek; 2002; 103(3):359-70. PubMed ID: 12688180
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study.
Put N; Konings P; Rack K; Jamar M; Van Roy N; Libouton JM; Vannuffel P; Sartenaer D; Ameye G; Speleman F; Herens C; Poirel HA; Moreau Y; Hagemeijer A; Vandenberghe P; Michaux L;
Genes Chromosomes Cancer; 2009 Oct; 48(10):843-53. PubMed ID: 19582829
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
[TBL] [Abstract][Full Text] [Related]
20. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
